生殖器疣：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國生殖器疣市場預計將從 3.9 億美元成長到 5.7 億美元，反映出市場強勁擴張。
• 市場成長受以下因素驅動：
• 高復發率導致需要反覆治療。
• 持續使用基於治療和局部治療的療法
• 儘管已有預防性疫苗，但現有患者群體和治療需求仍支撐著市場規模。
• 公眾意識的提高和篩檢發展，使得診斷率和治療率都得到了改善。
• 未來的市場動態將取決於疫苗接種率的提高和更永續治療方法的開發。

生殖器疣概述

生殖器疣，臨床上稱為尖形濕疣，是一種傳染性極強的良性上皮增生，主要由低危險型人類乳突病毒（HPV）6型和11型引起。這些感染疾病主要透過皮膚接觸傳播，病毒會攻擊基底層角質形成細胞並整合到上皮組織中。雖然大多數免疫功能正常的人可以部分抑制病毒複製，但免疫清除不徹底往往會導致持續感染和病變復發。

臨床上，生殖器疣表現為肛門和生殖器區域柔軟、肉色、外生性腫瘤，具有典型的「菜花狀」形態。組織病理學上，空泡細胞的存在（以核週透明化和異型性為特徵）是確診的關鍵特徵。儘管生殖器疣為良性，但它會造成嚴重的社會心理負擔，包括恥辱感、焦慮和生活品質下降，並且由於其頻繁復發和反覆治療，也給醫療保健系統帶來負擔。

目前的治療模式並非根治性，而是更著重於清除病灶而非根除病毒。治療策略包括患者自行用藥，例如咪喹莫特（一種免疫調節劑）和鬼臼樹脂（一種抗有絲分裂劑），以及醫護人員實施的治療方法，例如冷凍療法、三氯乙酸外敷、雷射療法或手術切除。儘管有這些治療選擇，但由於病毒持續存在於周圍組織中，復發率仍然很高。

九價人類乳突病毒(HPV)疫苗的廣泛應用已顯著降低了疾病發生率和感染率，治療趨勢也日益轉向預防策略。未來的研究方向將著重於提高治療效果的永續性、降低復發率以及擴大疫苗接種率，以期在人群層面實現疾病的長期控制。

主要亮點

• 據預測，義大利生殖器疣病例數將從 945,224 例增加到 1,013,513 例，這表明儘管採取了疫苗接種措施，但疾病負擔仍在加重。
• 持續的病毒攜帶和根治性的治療方法意味著高復發率仍然是一個嚴峻的挑戰。
• 這種疾病對心理社會和生活品質 (QOL) 方面的影響比其臨床症狀更大。
• 隨著人類乳突病毒(HPV)疫苗疫苗接種計劃的普及，預計發病率將逐漸下降，尤其是在年輕一代。
• 治癒性治療方法的創新不足凸顯了對持久性、標靶病毒治療方法的迫切需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Merck Sharp &Dohme LLC
• Shanghai Bovax Biotechnology Co., Ltd.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Genital Warts Market Outlook

Thelansis's "Genital Warts Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Genital Warts treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Genital Warts Overview

Genital warts, clinically known as condylomata acuminata, are highly contagious, benign epithelial proliferations caused predominantly by low-risk human papillomavirus (HPV) types 6 and 11. These infections are transmitted primarily through direct skin-to-skin sexual contact, with the virus targeting basal keratinocytes and integrating into epithelial tissue. While most immunocompetent individuals can partially control viral replication, incomplete immune clearance often leads to persistent infection and recurrent lesion formation.

Clinically, genital warts present as soft, flesh-colored, exophytic growths with a characteristic "cauliflower-like" morphology, affecting the anogenital region. Histopathologically, the presence of koilocytosis-marked by perinuclear clearing and nuclear atypia-remains a defining diagnostic feature. Although benign, the disease imposes a substantial psychosocial burden, including stigma, anxiety, and reduced quality of life, in addition to healthcare system strain due to frequent recurrences and repeat treatments.

The current therapeutic paradigm is non-curative, focusing on lesion removal rather than viral eradication. Treatment strategies include patient-applied therapies such as imiquimod (immune response modifier) and podofilox (antimitotic agent), alongside provider-administered modalities like cryotherapy, trichloroacetic acid application, laser therapy, or surgical excision. Despite these options, recurrence rates remain high due to viral persistence in surrounding tissues.

The landscape is increasingly shifting toward preventive strategies, with widespread adoption of the 9-valent HPV vaccine demonstrating significant impact in reducing incidence and transmission. Future directions emphasize improving therapeutic durability, reducing recurrence, and expanding vaccination coverage to achieve long-term disease control at the population level.

Key Highlights

• In Italy, prevalent cases of genital warts are projected to increase from 945,224 to 1,013,513, indicating a growing disease burden despite vaccination efforts.
• High recurrence rates remain a defining challenge due to persistent viral reservoirs and non-curative treatment approaches.
• The disease carries a significant psychosocial and quality-of-life burden, beyond its clinical manifestation.
• Increasing uptake of HPV vaccination programs is expected to gradually reduce incidence, particularly in younger populations.
• Limited innovation in curative therapies highlights a continued unmet need for durable and virus-targeting treatments.

Market Overview

• The France genital warts market is projected to grow from $390M to $570M, reflecting strong market expansion.
• Market growth is driven by:
• High recurrence leading to repeat treatment cycles
• Continued use of procedure-based and topical therapies
• Despite preventive vaccination, market value remains supported by existing prevalent patient pool and treatment demand.
• Increasing awareness and screening contribute to higher diagnosis and treatment rates.
• Future market dynamics will depend on vaccination coverage expansion and development of more durable therapeutic options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Shanghai Bovax Biotechnology Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)